Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.A new survey from CRB shows that most life sciences companies, particularly smaller biotechs, are not planning new investments in response to tariffs. The majority of manufacturing initiatives in the U.S. made in response to tariffs are coming from big pharma companies. Sky Bioscience's CB1 inhibitor, Nimacimab, showed promising weight-loss results when combined with Wegovy despite falling short of expectations in a mid-stage obesity trial. Amgen will offer its lipid-lowering drug Repatha directly to patients at a 60% discount. Biospace has honored 40 under 40 leaders in biopharma whose achievements reflect the industry's grit and impact. Pfizer beat out two other suitors for a takeover of Metsera. Maplight seeks a $227 million IPO for its neuropsych portfolio.AMT designation is taking its first steps amid uncertain benefits. Pharming's restructuring triggers a 20% reduction in its workforce. Experts are forging new paths to address scalability, cost, and other barriers surrounding cell therapy production.The CDC has adopted ACIP recommendations on chickenpox and COVID-19 vaccines. Stay tuned for upcoming events such as webinars on mRNA medicine, biopharma deregulation, and transforming digital sequences into mRNA.Various job opportunities in the life sciences industry include positions at Sonothera, Eli Lilly and Company, and Amgen.

Support the show